Amino.Desk

Retatrutide + cagrilintide blend

Updated Nov 17, 2026 · Clinical review: pending

This blend combines retatrutide and cagrilintide in one product. It is sold for maximum weight loss. Neither drug is approved, they belong to rival companies, and we found no trial that has combined them.

What it is

A premixed product sold by peptide suppliers and some clinics. The ingredients:

The idea copies CagriSema, which pairs cagrilintide with semaglutide and has been through large trials as a single product. Swapping in retatrutide makes a different combination that has not.

What the evidence shows

We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown.

Each drug has strong trial results on its own, in monitored studies with set doses and slow step-ups. Stacking two potent appetite drugs is not a small change. The side effects of each are mostly in the stomach and gut, and they would be expected to add up.

Legal status

Reported dosing

No dose has been established for this blend.

No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.

Safety

Common questions

What is in this blend?

Retatrutide and cagrilintide.

Has this blend been tested in people?

We found no human trial of the combination.

Is this blend legal?

No. Both ingredients are investigational drugs with no lawful route outside a clinical trial.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy